IP Library Granted Patent US 12,685,654
Granted Patent B2
US 12,685,654 · App. 18/378,301 · Granted Jul 21, 2026

Systems and methods for implants and deployment devices

Inventors: Marcel Song Sicotte (San Francisco, CA); Shreya Mehta (San Francisco, CA); Austin M. Bly (San Clemente, CA); Ronald Jabba (Redwood City, CA)
Assignee: ZENFLOW, INC.
A61F2/966A61F2/885A61B17/3468A61F2002/048A61F2/9517
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,685,654
App. No.
18/378,301
Filed
Oct 10, 2023
Granted
Jul 21, 2026
Kind
B2
Art Unit
3774
USPC
623/23.66
Abstract

Benign prosthetic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. Treatment options for BPH include medication, surgery (e.g., removal of enlarged prostate tissue), and minimally invasive procedures (e.g., needle ablation, electrovaporization, thermotherapy, and stent insertion). Minimally invasive procedure is typically the preferred choice if medication is ineffective. Accordingly, disclosed herein are system and method for treating BPH using improved implant and delivery device. Certain embodiments of the delivery device can include: a camming barrel having a first groove at the distal end of the camming barrel; a sheath, located within a lumen of the camming barrel, for storing the implantable device; and a first cam follower coupled to the sheath.

Claims (16)

1 . A method of delivering an expandable implant within a patient's urethra, the method comprising:

advancing within the urethra a distal end of a sheath housing the implant in a biased, delivery configuration, an elongate grasper slidable within the sheath and releasably coupled with a proximal portion of the implant during the advancing,

causing relative motion between the elongate grasper and the sheath to expose a distal portion of the implant from within the sheath such that the exposed distal portion of the implant transitions towards its default, deployed configuration, and into engagement with a wall of the urethra to maintain the urethra in an at least partially open state;

with the exposed distal portion of the implant maintaining the urethra in the at least partially open state and the proximal portion of the implant still housed within the sheath and releasably coupled with the elongate grasper, causing further relative motion between the elongate grasper and the sheath to expose the proximal portion of the implant from the sheath and release the implant from the elongate grasper; and

with the implant released from the elongate grasper, withdrawing the sheath and the elongate grasper from the urethra, leaving the implant in its default, deployed configuration, and in engagement with the wall of the urethra to maintain the urethra in the at least partially open state.

2 . The method of claim 1 , wherein causing the relative motion includes distally advancing the elongate grasper.

3 . The method of claim 1 , wherein the proximal portion of the implant defines a coupler and the elongate grasper defines a cavity into which the coupler of the implant is releasably coupled during the advancing.

4 . The method of claim 3 , wherein the coupler is a rounded enlarged atraumatic end of the implant.

5 . The method of claim 1 , wherein the implant is self-expandable from the biased, delivery configuration, in which the implant is in a lineated state, towards the default, deployed configuration, in which the implant has a greater lateral width and a shorter longitudinal length than the lineated state.

6 . The method of claim 1 , wherein the implant has a distal portion that, in the default, deployed configuration, assumes a first ring-shaped structure and a second ring-shaped structure spaced from the first ring-shaped structure, and wherein causing the relative motion between the elongate grasper and the sheath to expose the distal portion of the implant from within the sheath includes allowing the first ring-shaped structure and the second ring-shaped structure to engage with the wall of the urethra, while the elongate grasper remains releasably coupled with the proximal portion of the implant.

7 . The method of claim 6 , further comprising:

viewing the first ring-shaped structure and the second ring-shaped structure engaged with the wall of the urethra while the elongate grasper remains releasably coupled with the proximal portion of the implant.

8 . The method of claim 1 , wherein causing the relative motion between the elongate grasper and the sheath to expose the distal portion of the implant from within the sheath includes transitioning the implant into a partially deployed state in which the distal portion of the implant has radially expanded into engagement with the wall of the urethra while the proximal portion of the implant is still releasably coupled with the elongate grasper.

9 . The method of claim 8 , further comprising:

with the distal portion of the implant radially expanded and engaged with the wall of the urethra while the proximal portion of the implant is releasably coupled with the elongate grasper, withdrawing the elongate grasper relative to the sheath to withdraw the distal portion of the implant into the sheath and transition the implant towards its biased, delivery configuration.

10 . The method of claim 1 , wherein the implant is a unitary structure.

Continuity (5)
Continuation 17177772 · Feb 17, 2021
Division 16155506 · Oct 9, 2018
Continuation PCTUS2017028677 · Apr 20, 2017
Provisional Application 62325939 · Apr 21, 2016
Related Publication 20240225871A1 · Jul 11, 2024
References Cited (61)
US 4813925A · Anderson et al. · 1989 [cited by applicant]
US 5490860A · Middle et al. · 1996 [cited by applicant]
US 5830228A · Knapp et al. · 1998 [cited by applicant]
US 6371953B1 · Beyar et al. · 2002 [cited by applicant]
US 7192440B2 · Andreas et al. · 2007 [cited by applicant]
US 7678132B2 · Abbott · 2010 [cited by examiner]
US 8708953B2 · Salahieh et al. · 2014 [cited by applicant]
US 10952885B2 · Sicotte · 2021 [cited by examiner]
US 11497637B2 · Huang · 2022 [cited by examiner]
US 11571215B2 · Shelton, IV et al. · 2023 [cited by applicant]
US 11903859B1 · Sicotte · 2024 [cited by examiner]
US 12414850B2 · Mehta · 2025 [cited by examiner]
US 20040260382A1 · Fogarty et al. · 2004 [cited by applicant]
US 20050137716A1 · Gross · 2005 [cited by applicant]
US 20060052821A1 · Abbott · 2006 [cited by examiner]
US 20060276909A1 · Gellman · 2006 [cited by applicant]
US 20080015633A1 · Abbott et al. · 2008 [cited by applicant]
US 20080249466A1 · Aubert et al. · 2008 [cited by applicant]
US 20100198333A1 · Macatangay et al. · 2010 [cited by applicant]
US 20100222802A1 · Gillespie, Jr · 2010 [cited by examiner]
US 20110093007A1 · Abbott et al. · 2011 [cited by applicant]
US 20130006048A1 · Fisher · 2013 [cited by applicant]
US 20140172065A1 · Lavelle · 2014 [cited by examiner]
US 20140288627A1 · Ouellette et al. · 2014 [cited by applicant]
US 20150257908A1 · Chao · 2015 [cited by examiner]
US 20160262862A1 · Fischer · 2016 [cited by applicant]
US 20170065406A1 · Calomeni et al. · 2017 [cited by applicant]
US 20170333042A1 · Sato · 2017 [cited by examiner]
US 20190038443A1 · Sicotte et al. · 2019 [cited by applicant]
US 20190117423A1 · Chao et al. · 2019 [cited by applicant]
US 20190307548A1 · Sicotte et al. · 2019 [cited by applicant]
US 20200038213A1 · Bly et al. · 2020 [cited by applicant]
US 20200146823A1 · Alon et al. · 2020 [cited by applicant]
US 20200323618A1 · Bly et al. · 2020 [cited by applicant]
US 20210038885A1 · Grace et al. · 2021 [cited by applicant]
US 20210161642A1 · Jen · 2021 [cited by examiner]
US 20210275335A1 · Sicotte et al. · 2021 [cited by applicant]
US 20220015792A1 · Grace et al. · 2022 [cited by applicant]
US 20220039970A1 · Elliot · 2022 [cited by applicant]
US 20220110737A1 · Mehta · 2022 [cited by examiner]
CA 2939823A1 · 2014 [cited by applicant]
CN 101247777A · 2008 [cited by applicant]
CN 102065794A · 2011 [cited by applicant]
CN 104470471A · 2015 [cited by applicant]
EP 1321111A2 · 2003 [cited by applicant]
EP 2839872A1 · 2015 [cited by applicant]
EP 1887976B1 · 2022 [cited by examiner]
WO WO9626682A1 · 1996 [cited by applicant]
WO WO2005016185A1 · 2005 [cited by applicant]
WO WO2007005799A1 · 2007 [cited by applicant]
WO WO2011102968A1 · 2011 [cited by applicant]
WO WO2012036741A2 · 2012 [cited by applicant]
WO WO2012123950A2 · 2012 [cited by applicant]
WO WO2016022899A1 · 2016 [cited by applicant]
WO WO2021250588A1 · 2021 [cited by examiner]
CN, 202110884875.2 Third Office Action, Apr. 15, 2024. [cited by applicant]
CN, 202110884875.2 First Office Action, Oct. 27, 2023. [cited by applicant]
CN, 202110884875.2 Second Office Action, Feb. 28, 2024. [cited by applicant]
CN, 201780024866.8 First Office Action, Apr. 14, 2020. [cited by applicant]
EP, 17786650.6 Supplementary Search Report, Nov. 21, 2019. [cited by applicant]
WO, PCT/US2017/028677 ISR and Written Opinion, Aug. 14, 2017. [cited by applicant]